Related Experiment Video
Updated: Jul 19, 2025
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Multi-Target Neural Differentiation (MTND) Therapeutic Cocktail to Suppress Brain Tumor
Xiaoping Hu1, Jingdun Xie2, Yilin Yang1
1School of Biomedical Engineering, Sun Yat-sen University, Guangzhou 510275, China.
Abstract:
Brain tumors have been proved challenging to treat. Here we established a Multi-Target Neural Differentiation (MTND) therapeutic cocktail to achieve effective and safe treatment of brain malignancies by targeting the important hallmarks in brain cancers: poor cell differentiation and compromised cell cycle. In-vitro and in-vivo experiments confirmed the significant therapeutic effect of our MTND therapy. Significantly improved therapeutic effects over current first-line chemo-drugs have been identified in clinical cells, with great inhibition of the growth and migration of tumor cells. Further in-vivo experiments confirmed that sustained MTND treatment showed a 73% reduction of the tumor area. MTND also induced strong expression of phenotypes associated with cell cycle exit/arrest and rapid neural reprograming from clinical glioma cells to glutamatergic and GABAergic expressing cells, which are two key neuronal types involved in many human brain functions, including learning and memory. Collectively, MTND induced multi-targeted genotypic expression changes to achieve direct neural conversion of glioma cells and controlled the cell cycle/tumorigenesis development, helping control tumor cells' malignant proliferation and making it possible to treat brain malignant tumors effectively and safely. These encouraging results open avenues to developing new therapies for brain malignancies beyond cytotoxic agents, providing more effective medication recommendations with reduced toxicity.
Insights
A novel Multi-Target Neural Differentiation (MTND) therapy effectively treats brain tumors by reprogramming cancer cells and controlling their cycle. This approach shows significant tumor reduction and offers a safer alternative to chemotherapy.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
- Cellular Reprogramming
Background:
- Brain tumors present significant treatment challenges due to poor cell differentiation and compromised cell cycle regulation.
- Current therapies often lack efficacy and are associated with considerable toxicity.
Purpose of the Study:
- To develop and evaluate a novel therapeutic cocktail, Multi-Target Neural Differentiation (MTND), for effective and safe brain tumor treatment.
- To target key hallmarks of brain cancers: poor cell differentiation and compromised cell cycle.
Main Methods:
- In-vitro and in-vivo experiments were conducted to assess the efficacy of the MTND therapy.
- MTND therapy was compared against current first-line chemotherapy drugs using clinical glioma cells.
- Tumor growth, migration, and cellular phenotypes were analyzed post-treatment.
Main Results:
- MTND therapy demonstrated significant therapeutic effects, outperforming current chemotherapy drugs in clinical cell studies.
- Sustained MTND treatment resulted in a 73% reduction in tumor area in in-vivo models.
- MTND induced neural reprogramming of glioma cells into glutamatergic and GABAergic neurons, coupled with cell cycle arrest.
Conclusions:
- MTND therapy effectively targets brain tumor hallmarks, inducing neural conversion and controlling cell cycle progression.
- This approach offers a promising, safer alternative to cytotoxic agents for treating malignant brain tumors.
- MTND opens new therapeutic avenues for brain malignancies, emphasizing reduced toxicity and improved efficacy.
